There's more to Teva than meets the eye

Our mission is to be a global leader in generics and biopharmaceuticals, improving the lives of patients across the world

Teva is a big player on the world stage - that brings considerable benefits to patients in Ireland

01

Enabling access to high quality medicines and treatment options

1,800
medicines
40,000
employees
200,000,000
patients

At Teva we believe that everyone should have access to high quality medicine that helps manage disease, fights infection, or simply improves overall health

We develop, produce and market affordable generic medicines, as well as innovative and specialty pharmaceuticals and biologics, and over-the-counter consumer healthcare products. That’s along with supplying active pharmaceutical ingredients to nearly 1,000 customers in over 100 countries.

Our diverse family of over 40,000 employees is the beating heart of our company, working together to find innovative and creative solutions to the healthcare challenges of today and tomorrow.

As the global leader in generic medicines, nearly 200 million patients across six continents take one of our products every day. 01

02

Concentrating our efforts on core therapeutic areas

We focus on developing, personalising and improving treatment of disorders of the central nervous system, migraine, respiratory conditions, oncology and pain management.

We are exploring healthcare options that are fit for the future; like new technologies, innovative devices, and a fresh approach to services.

Central Nervous System

Movement disorders and neurodegeneration

Migraine

Chronic and episodic migraine

Respiratory

Asthma and chronic lung diseases

Oncology & Pain

Pain management and cancer therapies

We play an important role in delivering value to healthcare systems and economies around the world

The scale of production and accessible price of our products help to limit rising healthcare costs and improve patient health outcomes.

We also invest hundreds of millions of euros every year to enable our scientists to develop specialty and biopharmaceutical treatments that aim to improve patients’ health and increase access to medicines.

03

Delivering value to Ireland’s Healthcare System

In 2013 Ireland introduced compulsory generic medicines substitution and now, several years on, we’re seeing the real economic impact of that initiative.

Back in 2013 generic usage in the Irish medicines market was 11% but that figure rose to 58% in 2018. 02

An estimated €1.6 billion in medicine savings was realised over the period 2013-2018, solely from generic substitution. 03

Teva as the largest supplier of prescription medicines to the Health Service Executive 04 and a key partner to pharmacy in Ireland, has played an integral part in helping to drive these changes.

Billion
1.6
Estimated savings between 2013-2018

The chances are, someone you know is living a healthier life, because of our medicines - after all, we are the largest supplier of prescription medicines to Irish pharmacies 04

1 in 8 prescription packs supplied to Irish pharmacies is a Teva medicine
In Ireland, a Teva pack is used every 3 seconds
04

Investing in our operations in Ireland

Teva is a major employer in Ireland with hundreds of highly skilled colleagues working in our research and manufacturing facilities

We employ around 800 people with sites in Dublin, Baldoyle and Waterford. We are committed to investing in Ireland and proud of our contribution to GDP. 05

400
we invested more than €400m over 10 years
3
Dublin, Baldoyle and Waterford
350
we contribute over €350m annually to GDP

Our commercial teams and support functions are based in Swords, near Dublin, they are complemented by field-based sales teams covering both primary and secondary care in Ireland.

The Waterford site is of major strategic importance within the Teva manufacturing network and is responsible for the manufacture and development of respiratory medicines and devices. It includes a research and development centre dedicated to the next generation respiratory devices and smart technologies for the treatment of respiratory conditions like asthma and Chronic Obstructive Pulmonary Disease. We’re proud to say that Waterford consistently achieves excellent inspection outcomes from multiple regulatory agencies around the world.

Since 1984 Baldoyle has been a manufacturing site for the over-the-counter medication Sudocrem®, first developed in 1931 and now a multi-award winning, globally recognised product sold in over 50 countries. Sudocrem® Antiseptic Healing Cream is an absolute staple in Irish households, loved by Irish families for its ability to soothe cuts, grazes, bed sores, sunburn, eczema as well as nappy rash.

05

Leveraging our global size and strength

Teva is a big player on the world stage - that brings considerable benefits to patients in Ireland 

We are continually expanding our range of medicines, devices and services to better meet the needs of Irish patients and to offer increased choice to healthcare professionals.

65
production sites
85
billion tablets & capsules annually
25
R&D and clinical development sites

We produce approximately 85 billion tablets and capsules a year through our 65 manufacturing facilities in more than 30 countries. 06

We have a strong pipeline of innovative medicines at various developmental stages and we are actively investigating novel uses for existing treatments.

06

Improving health, enabling better days

Right now all across the country…

  • An Irish parent is trusting a Teva medicine to help a sick child get well
  • An Irish doctor is writing a prescription for a Teva medicine, to improve her patient’s health outcome
  • An Irish pharmacist is reaching for a Teva product, secure in the knowledge that Teva medicines meet the highest standards for quality and safety
1,800
medicines
1,500
community pharmacies
5
million people in Ireland

And that means all across Ireland, people you probably know are living a healthier life because of our medicines

References

  1. Back to contents.

    Internal analyses conducted by Global Insights, Access & Technologies estimating number of Teva consumers. Ref 2.1 dated August 2016; Ref 2.2 dated April 2019

  2. Back to contents.
  3. Back to contents.

    Based on Medicines for Ireland company and IMS data https://www.medicinesforireland.ie/wp-content/uploads/2017/06/Medicines_for_Ireland-Generics@5.pdf Accessed December 2020

  4. Back to contents.

    Teva Ireland Data On File

  5. Back to contents.

    Teva Economic Impact Report - Matrix Global Advisors estimate of Teva’s Macroeconomic Impact in Ireland in 2018

  6. Back to contents.

    Teva Global Operations - Internal Data Source

Date of preparation: December 2020
Reference: COB-IE-NP-00046